The pharmaceutical startup has struggled to raise enough capital to cover the costs of its operations and clinical trials: “Following this offering, we will need to raise additional capital to fund our operations and continue to support our planned development and commercialization activities,” an SEC filing from Cingulate reads.Cingulate prepares another stock offering to raise money amid funding crunch
The pharmaceutical startup has struggled to raise enough capital to cover the costs of its operations and clinical trials: “Following this offering, we will need to raise additional capital to fund our operations and continue to support our planned development and commercialization activities,” an SEC filing from Cingulate reads.